Novogen Ltd. to launch website for ovarian cancer drug study

Novogen Ltd. ADS (Nasdaq: NVGN) said this morning that a new website has been launched to recruit patients for a Phase III clinical trial of an investigational ovarian cancer drug phenoxodiol, called OVATURE (OVArian TUmor REsponse).

According to the Australian company, the goal of the website is to inform ovarian cancer patients about the company’s trial, including eligibility, trial locations and participating doctors. The website will also provide information on the actual drug, phenoxodiol, being tested.

The trial will study the safety and effectiveness of the drug phenoxodiol, which has not yet been approved for marketing by the Food and Drug Administration, when used in combination with weekly doses of the chemotherapy drug carboplatin.

Novogen said that patients whose ovarian cancer initially responded to chemotherapy, but has since become resistant to traditional treatments, are eligible to participate.

Hospitals and treatment centers throughout the United States, Europe and Australia are serving as trial sites.

The website is www.OVATUREtrial.com.

Shares of Novogen slid $0.41, or 5.24%, to $7.42 in morning trading.

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below